American Diabetes Association Scientific Sessions
Lessons learned at American Diabetes Association’s 74th Scientific Sessions
The American Diabetes Association’s 74th Scientific Sessions, held in San Francisco, addressed various emerging areas of study in the treatment of type 1 and type 2 diabetes.
Diabetes management by mid-level providers comparable to physicians
SAN FRANCISCO — The quality of diabetes management by mid-level providers is equivalent to that provided by primary care physicians, according to research presented at the American Diabetes Association’s 74th Scientific Sessions.
Ultra-widefield imaging improved diabetic retinopathy detection
SAN FRANCISCO — Ultra-widefield imaging with or without fluorescein angiography could have significant implications for identifying and treating diabetic retinopathy, according to data presented at the American Diabetes Association’s 74th Scientific Sessions.
Microaneurysms shed light on diabetic retinopathy
SAN FRANCISCO — The identification of microaneurysm wall features have been correlated with anatomic and functional outcomes in the eyes of diabetes patients, according to data presented at the American Diabetes Association’s 74th Scientific Sessions.
RETeval device a viable option for diabetic retinopathy screening
SAN FRANCISCO — The RETeval device may be a promising new screening tool for diabetic retinopathy due to its ease of use and low failure rates, according to late-breaking data presented at the American Diabetes Association’s 74th Scientific Sessions.
Preliminary data indicate Singulair as potential diabetic retinopathy therapy
SAN FRANCISCO — Leukotriene B4 receptor 1 levels, leukotriene B4 generation and superoxide production may be potential pathogenic markers for diabetic retinopathy in young patients with type 1 diabetes, according to study data presented here.
Data lack support for retinal exams in youth with diabetes
SAN FRANCISCO — Evidence does not support routine retinal screenings of pediatric patients with type 1 diabetes based solely on age and diabetes duration, according to a researcher here.
Brain responses to hypoglycemia raise questions regarding recovery
SAN FRANCISCO — Patients with type 1 diabetes with impaired awareness of hypoglycemia show different brain activation patterns than patients with greater awareness, according to research presented at the American Diabetes Association’s 74th Scientific Sessions.
Weight management linked to better postpartum glycemic control
SAN FRANCISCO — A study examining postpartum fasting plasma glucose during the postpartum period showed that those in a weight management program had better glycemic control than their counterparts, according to a presenter at the American Diabetes Association’s 74th Scientific Sessions.
Empagliflozin safe, effective treatment for type 2 diabetes
SAN FRANCISCO — Empagliflozin used as monotherapy or as an add-on medication improved outcomes for patients with type 2 diabetes, according to research presented at the American Diabetes Association’s 74th Scientific Sessions.